Summary We measured tumour cellular DNA in 102 patients entered into two phase III trials of chemotherapy for end stage squamous carcinoma of the head and neck. The median survival of untreated patients with aneuploid tumours was 55 days compared with 224 days for patients treated with cisplatinum. This difference was highly significant. In contrast the median survival of untreated patients with diploid tumours was 74 days compared with 118 days for treated patients. Although this difference is statistically significant, the increased survival of 6 weeks is of no clinical benefit compared with the prolongation of survival of 6 months in patients with aneuploid tumours. Multivariate analysis showed that the significant predictors of survival were Karnofsky status, response to chemotherapy and ploidy.
The relationship of ploidy to prognosis in solid tumours has been widely studied. In general patients with diploid tumours have been found to have a more favourable prognosis than those with aneuploid cancers (Cornelisse et al., 1987; Joensuu et al., 1986; Zimmerman et al., 1987) . Relatively few studies of squamous cell carcinoma of the head and neck have been reported and not all agree that aneuploidy confers a poor prognosis (Goldsmith et al., 1987) . However, recent studies of resectable squamous cell carcinoma suggest a poor outcome for those with an aneuploid DNA content (Kokal et al., 1988) .
There is preliminary evidence that DNA ploidy may also predict response to cytostatic therapy. In certain leukaemias treated by chemotherapy, the aneuploid tumours are the most responsive (Barlogie et al., 1987) . In order to test this hypothesis on solid tumours we have assessed the effect of ploidy in cancers from patients entered into two phase III prospective randomised trials of chemotherapy for end stage squamous carcinoma of the head and neck (Morton et al., 1985; Allison et al., 1989) .
Entry into these trials was confined to patients with locally advanced or recurrent squamous cell cancers (Miller et al., 1981) .
Flow cytometric analysis Thick sections were examined by flow cytometry. Consecutive 5 tim sections were stained by haematoxylin and eosin to confirm the presence of tumour in all samples studied. Nuclei were extracted from formalin fixed paraffin embedded tissue (Hedley et al., 1983 (Peto, 1977) with analysis for trend where appropriate, and significant prognostic factors were then subjected to multivariate analysis using Cox's regression analysis.
Staging andfollow-up
All the tumours were classified by the latest TMN scheme (UICC, 1988) Tables I and II . There was no significant relationship between any of these parameters and ploidy.
Chemotherapy The mean number of courses of cisplatinum received by the group of patients with diploid tumours was 2.5 and that by the group with aneuploid tumours was 2.6
Relationship ofploidy to response Twenty-two (40%) of the treated patients had a partial or complete response to cisplatinum. Of the 22 diploid tumours, eight (36%) patients showed a partial or complete response compared with 14 of 30 (47%) aneuploid tumours. This difference was not significant (X2 = 2.92) (Table III) .
Relationship ofploidy to survival The median survival of untreated patients with diploid tumours was 74 days and of those with aneuploid tumours 55 days, but this difference did not reach statistical significance (X2 = 1.72) (Figure 1) . The median survival of treated patients with aneuploid tumours was 224 days and the increased survival of this treated group was significantly longer than that for patients with untreated aneuloid cancers (X2 = 20.7, P <0.001) (Figure 2) . The median survival of treated patients with diploid tumours was 118 days and this was significantly longer than the median survival of untreated patients with diploid tumours (X2 = 7.31, P<0.01) ( Figure   3 ).
Prognostic factors
Cox's regression analysis showed that age, sex, site of disease, histological grading and previous treatment were not significant prognostic factors. Karnofsky status and response to chemotherapy were both highly significant predictors of survival (P<0.001). An aneuploid tumour DNA content was also found to be a significant predictor of survival (P <0.025). Stage was not included in this analysis as most tumours were in stage IV. 
Discussion
Analysis of DNA content can provide important prognostic information in a variety of malignant neoplasms. Abnormal cellular DNA contents clearly worsen the prognosis in breast carcinoma (Cornlisse et al., 1987) , bronchial carcinoma (Zimmerman et al., 1987) , colorectal carcinoma (Armitage et al., 1985) , prostatic carcinoma (Fordham et al., 1986 ) and squamous cell carcinoma at sites outside the head and neck, such as the lung (Blondal, 1981) and cervix (Jakobsen, 1984 No relationship was shown between ploidy and histological grade by Kaplan et al. (1986 ), Johnson et al. (1985 and Ensley et al. (1989) but the frequency of DNA non-diploid tumours was found to correlate with a decrease in the histological grading by Holm (1982 ), Tytor et al. (1987 ) and Feichter et al. (1987 , who also found that it was directly proportional to the percentage of cells in S-phase. We found no correlation between the degree of histological differentiation and DNA content. However, a parallel study of the histopathology of these carcinomas has revealed other morphological features which correlate with ploidy, diploid carcinomas having prominent nucleoli and a lower surface area to volume ratio of the groups of tumour cells (Helliwell et al., 1989) .
No significant relationship between ploidy and tumour stage was found by Feichter et al. (1987) , Holm (1982) and Ensley et al. (1989) , whereas Kaplan et al. (1986) , Kokal et al. (1988) and Tytor et al. (1989) reported a higher incidence of aneuploidy in advanced tumours.
Data relating clinical outcome to DNA content in larger series of patients treated in a uniform manner are few. Kokal et al. (1988) studied a group of 76 patients with surgically resectable lesions of the oral cavity, larynx and pharynx. Those patients with aneuploid cancers had significantly lower relapse-free and overall survival rates, and Cox's regression analysis showed tumour DNA content to be an independent prognostic factor. In surgically treated squamous cell carcinoma of the oesophagus a high hyperploid DNA content was an independent prognostic factor indicating a poor prognosis (Matsuura et al., 1986) .
In a large series of oral cavity carcinomas (Tytor et al., 1989) , stage I and II aneuploid tumours had a worse prognosis, but the reverse was true for stages III and IV which were mostly treated by combined surgery and radiotherapy or radiotherapy alone. A previous observation that aneuploid tumours responded better to preoperative radiotherapy (Franzen et al., 1986) was further confirmed in this later study, and may account for the reversal of the prognosis for those with stage III and IV aneuploid tumours. This finding may also explain the report by Goldsmith et al. (1986) that, among a heterogeneous group of patients with laryngeal carcinoma, the aneuploid tumours had a better prognosis as all but five of the 48 patients received radiotherapy as part of their treatment. Franzen et al. (1986) also showed that the mean S-phase value was higher (16.1%) in those tumours that were eradicated by preoperative radiotherapy than for those that did not respond (8.1%). A strong direct correlation between the degree of DNA aneuploidy and S-phase fraction has been reported for squamous carcinomas of the head and neck (Ensley et al., 1989) as well as a number of different solid tumours (Barlogie et al., 1983) . This suggests that aneuploid tumours may be faster growing and therefore more susceptible to chemotherapy. In certain haematological malignancies treated by chemotherapy, such as adults with acute myelogenous leukaemia and children with acute lymphocytic leukaemia, aneuploidy has emerged as a favourable prognostic factor (Barlogie et al., 1987; Look et al., 1984) . Similarly hyperdiploid neuroblastomas in infants responded better to chemotherapy than diploid tumours (Look et al., 1985) .
Our results show a slightly longer median survival for patients with diploid tumours compared with those with aneuploid tumours receiving no further treatment. Paradoxically, response rates did not differ significantly between diploid and aneuploid tumours but survival did. This is further evidence of the unreliability of response in assessing the efficacy of chemotherapy.
Diploid tumours may be less susceptible to cytotoxic therapy, either because fewer cells are undergoing DNA synthesis, or because of undefined characteristics confering resistence that are independent of kinetic considerations.
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